Quanterix

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Quanterix reports strong Q4 revenue, eyes growth in neurology diagnostics

Quanterix's Q4 performance showcased revenue growth and margin improvement, underpinned by advancements in assay manufacturing and the launch of new tests. The company faces challenges in revenue management and cost control but has opportunities to drive growth through core products and competitive positioning in neurology diagnostics.

Quanterix reports robust Q1 earnings, eyes neuro research growth

Quanterix delivered strong Q1 results with revenue growth and margin improvements, while facing challenges in cash management and meeting revised guidance targets.
The company's focus on neuro research and clinical applications, along with its transformation plan, positions it well for future growth and market leadership.
Analyst inquiries highlighted areas for improvement and clarity, signaling the need for continued strategic communication and operational enhancements.

Quanterix reports robust Q2 earnings, eyes growth in diagnostics market

Quanterix's Q2 performance reflects strong revenue growth and improved profitability.
The company's focus on innovative diagnostics for Alzheimer's and neurological therapies positions it well for future growth.
Despite challenges in leadership transition and addressing specific patient needs, Quanterix remains optimistic about market adoption of blood biomarkers.

Quanterix reports strong Q3 revenue growth and advances in Alzheimer's diagnostics

Quanterix's Q3 performance reflects revenue growth, improved gross margins, and strategic collaborations in blood biomarker testing for Alzheimer's disease.
The company's strengths in expanding platform access, operational efficiency, and multimarker approaches present growth opportunities in diagnostics.
Challenges include meeting revenue growth expectations, maintaining high sensitivity levels in diagnostics, and balancing margin improvements with investments.
Opportunities exist in leveraging partnerships, developing innovative biomarker solutions, and capitalizing on the demand for comprehensive diagnostic tools in healthcare.

Quanterix reports record revenue in Q4 2023, eyes Alzheimer's diagnostics

Quanterix's Q4 2023 performance reflects strong revenue growth, improved margins, and strategic focus on innovation and market expansion.
While challenges in capital allocation and sustaining growth persist, the company's opportunities in menu expansion and Alzheimer's diagnostics are promising.
Overall, Quanterix's financial outlook for 2024 appears positive, with a clear roadmap for growth and continued market penetration.

Quanterix reports revenue growth and innovation drive amidst competition challenges

Quanterix's Q1 2024 performance reflects revenue growth, margin improvement, and innovation in disease detection assays, positioning the company for future success.
Strategic strengths include strong gross margins, successful product launches, and growth in Accelerator Lab services, driving revenue and market presence.
Challenges include competition assessment, margin maintenance, and regulatory milestones, while opportunities exist in innovation, revenue growth, and profitability focus.

Quanterix reports robust Q3 earnings, eyes growth in Alzheimer's diagnostics

Quanterix's strong revenue growth, focus on innovation, and strategic priorities position the company for continued success in the diagnostics market.
While facing challenges in maintaining gross margins and navigating regulatory landscapes, Quanterix has opportunities to drive growth through advanced diagnostics and market expansion.
By balancing customer mix, expanding menu offerings, and investing in new technologies, Quanterix is poised to capitalize on the growing demand for precision medicine and Alzheimer's disease testing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quanterix's industry leading platform, which is highly levered to the growth in precision medicine, can detect protein biomarkers at significantly lower concentrations and at higher sensitivity vs competitors.

Quanterix: The Illumina Of Proteomics - Life Science Tools Play At A Reasonable Valuation

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the closing of its previously announced underwritten public offering of 3,048,774 shares of its common stock at a public offering price of $32.00 per share, including 397,666 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares.

Quanterix Announces Closing of Public Offering Including Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Quanterix Corporation (QTRX) CEO Kevin Hrusovsky on Q2 2020 Results - Earnings Call Transcript

Quanterix Corporation (QTRX) CEO Kevin Hrusovsky on Q1 2020 Results - Earnings Call Transcript

Quanterix (QTRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Quanterix (QTRX) Stock Stands Out in a Strong Industry

Quanterix Corporation (QTRX) CEO Kevin Hrusovsky on Q4 2019 Results - Earnings Call Transcript

Quanterix Corp (QTRX) CEO Kevin Hrusovsky on Q3 2019 Results - Earnings Call Transcript

Canopy Growth

Medtronic

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

3 Medical Product Stocks - Likely to Beat This Earnings Season

Quanterix Corporation (QTRX) CEO Kevin Hrusovsky on Q2 2019 Results - Earnings Call Transcript

Quanterix Corporation (QTRX) CEO Kevin Hrusovsky on Q1 2019 Results - Earnings Call Transcript

News for Quanterix Stock (QTRX)